287952-67-4

Basic information

• Product Name: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE
• Synonyms: Piperidine, 4-[4-(trifluoroMethoxy)phenoxy]-;4-[4-(TrifluoroMethoxy)phenoxy]piperidine HCl;Delamanid intermediate
• CAS NO: 287952-67-4
• Molecular Formula: C₁₂H₁₄F₃NO₂
• Molecular Weight: 261.25
• Mol File: 287952-67-4.mol

Chemical Properties

• Melting Point: 71-73℃
• Boiling Point: 292.2°Cat760mmHg
• Flash Point: 130.5°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 0.00151mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.65±0.10(Predicted)
• CAS DataBase Reference: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE(287952-67-4)
• EPA Substance Registry System: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE(287952-67-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 287952-67-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE is used as a key intermediate in the synthesis of 3,5-disubstituted isoxazolines, which are considered as potential antituberculosis agents. These agents are being explored for their ability to target and inhibit the growth of Mycobacterium tuberculosis, the causative agent of tuberculosis, a significant global health concern.
4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE's role in the development of antituberculosis agents is attributed to its structural features, which may facilitate the design of new drugs with improved efficacy and reduced side effects compared to existing treatments. By incorporating 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE into the molecular framework of isoxazoline-based drugs, researchers aim to enhance their ability to target and disrupt the vital processes within Mycobacterium tuberculosis, ultimately leading to the inhibition of the disease's progression.

InChI:InChI=1/C12H14F3NO/c13-12(14,15)9-1-3-10(4-2-9)17-11-5-7-16-8-6-11/h1-4,11,16H,5-8H2

Upstream product

• 287952-66-3 tert-butyl 4-(4-(trifluoromethoxy)phenoxy)piperidin-1-carboxylate 
• 1083099-51-7 1-ethoxycarbonyl-4-(4-trifluoromethoxy-phenoxy)-piperidine 
• 1083099-54-0 4-(4-trifluoromethoxy-phenoxy)-pyridine 
• 50824-05-0 4-trifluoromethoxybenzyl bromide 
• 828-27-3 4-Trifluoromethoxyphenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 287952-21-0 4-[(4-trifluoromethoxy)phenyl]methoxypiperidine-1-formic acid tert-butyl ester 
• 1501963-64-9 4-(4-(trifluoromethoxy)phenoxy)piperidine hydrochloride 
• 65214-82-6 4-hydroxy-piperidine-1-carboxylic acid ethyl ester 

Downstream Products

• 681482-80-4 1-[4-(tetrahydropyran-2-yloxy)phenyl]-4-(4-trifluoromethoxyphenoxy)piperidine 
• 308386-11-0 2-[4-(4-trifluoromethoxy-phenoxy)-piperidine-1-sulfonyl]-benzoic acid 
• 308385-94-6 N-(tetrahydro-pyran-2-yloxy)-2-[4-(4-trifluoromethoxy-phenoxy)-piperidine-1-sulfonyl]-benzamide 
• 701271-05-8 tert-butyl 4-[(2-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}-1,3-benzothiazol-6-yl)sulfonyl]tetrahydro-2H-pyran-4-carboxylate 
• 733751-05-8 (4-methanesulfonyl-phenyl)-{5-nitro-6-[4-(4-trifluoromethoxy-phenoxy)-piperidin-1-yl]-pyrimidin-4-yl}-amine 
• 681482-81-5 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine 
• 1083099-55-1 1-(4-benzyloxy-phenyl)-4-(4-trifluoromethoxy-phenoxy)-piperidine 
• 1145961-59-6 C₂₀H₂₀F₃NO₂ 
• 866109-93-5 4-(4-(4-trifluoromethoxy-phenoxy)piperidin-1-yl)phenol para-toluenesulfonic acid salt 
• 1318735-00-0 (R)-2-methyl-3-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)propane-1,2-diol 
• 1318735-08-8 4-[4-(trifluoromethoxy)phenoxy]-1-{4-[(2,2,4-trimethyl-1,3-dioxolan-4-yl)methoxy]phenyl}piperidine 
• 1318734-91-6 2-methyl-3-(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)propane-1,2-diol 
• 1318734-93-8 (S)-4-[4-(trifluoromethoxy)phenoxy]-1-{4-[(2,2,4-trimethyl-1,3-dioxolan-4-yl)methoxy]phenyl}piperidine 
• 1346017-83-1 ethyl 3-(4-((4-trifluoromethoxy)phenoxy)piperidin-1-yl)propionate 

Relevant articles and documents

METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF

The present invention provides a method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof, the method including the step of heating hydroquinone and 4-(4-trifluoromethoxyphenoxy)piperidine. This method can produce 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof in an industrially advantageous manner.

Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity

A series of pyrazolo[1,5-a]pyridine-3-carboxamide hybrids were designed and evaluated as novel anti-tubercular agents. The representative hybrid 7 exhibited promising in?vitro activity against susceptive strain H37Rv and a panel of drug-resistant Mtb strains with MIC values of 0.006?μg/mL and ranged from 0.003 to 0.014?μg/mL, respectively. More importantly, the hybrid 7 also showed very low cytotoxicity, and could significantly reduce the mycobacterial burden in a mouse model infected with autoluminescent H37Ra strain, which may serve as a lead compound for further development of new anti-tubercular agents.

Method for preparing highly pure Delamanid intermediate

The invention provides a method for preparing a highly pure delamanid intermediate. The intermediate is 4-[4-(trifluoromethoxy)phenoxyl]piperidine. Hydrogen chloride is dissolved in ethyl acetate in a Boc group removal step, and the dissolvability difference between the above product and impurities in ethylene acetate is used to carry out purification, so a column chromatography purifying method using tedious operation is avoided, the final product with high yield and high purity is also obtained, the production cost is reduced, and the method is suitable for industrial large-scale production.

Preparation method for 4-[4-(trifluoromethoxy)phenoxyl]piperidine

The invention discloses a preparation method for 4-[4-(trifluoromethoxy)phenoxyl]piperidine. The preparation method comprises the following steps: 1) synthesizing N-benzyl (or substituted benzyl)-4-[4-(trifluoromethoxy)phenoxyl]pyridinium salt from 4-[4-(trifluoromethoxy)phenoxyl]pyridine and a benzyl group or substituted benzyl halide; 2) reducing the product of the step 1) into N-benzyl (or substituted benzyl)-1,2,3,6-tetrahydro-4-[4-(trifluoromethoxy)phenoxyl]pyridine; 3) reacting the product of the step 2) with acid and a hydrogen source so as to produce 4-[4-(trifluoromethoxy)phenoxyl]pyridin salt; and 4) reacting the product of the step 3) with alkali so as to produce 4-[4-(trifluoromethoxy)phenoxyl]piperidine. The method provided by the invention prepares 4-[4-(trifluoromethoxy)phenoxyl]piperidine from 4-[4-(trifluoromethoxy)phenoxyl]pyridine, is reduced in production cost and improves product yield and purity.

(6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6-YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

(6,7-Dihydro-2-nitro-5H-imidazo [2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the descripti

(6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

(6,7-Dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the descriptio

PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS

The present invention relates to a process for the preparation of optionally substituted (N-heterocyclyl) aryl ethers.

EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME

The present invention provides a novel intermediate for manufacturing a 2,3-dihydroimidazo[2,1-b]oxazole compound with a high yield and a high purity, and a manufacturing method of the intermediate. The present invention provides an epoxy compound represe

METHOD OF PRODUCING AMINOPHENOL COMPOUNDS

The present invention provides an industrially advantageous method of producing aminophenol compounds represented by the formula (1) by a simple and easy procedure at a high yield and a high purity. The present invention provides a method of producing an aminophenol compound represented by the formula (1): (wherein each of R1 and R2, which may be the same or different, is a hydrogen atom, a substituted or unsubstituted lower alkyl group or the like; R1 and R2, taken together with the adjacent nitrogen atom, may form a 5- or 6-membered heterocycle with or without other intervening heteroatoms; the heterocycle may be substituted by 1 to 3 substituents selected from the group consisting of a hydroxyl group, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aryloxy group and the like; and the hydroxyl group in the formula (1) is substituted on the 2- or 4-position to the amino group on the phenyl ring), which comprises allowing a cyclohexanedione compound represented by the formula (2) to react with an amine compound represented by the formula (3) (wherein R1 and R2 are as defined above), under a neutral or basic condition.

Sulfamato hydroxamic acid metalloprotease inhibitor

A sulfamato hydroxamic acid compound that, inter alia, inhibits matrix metalloprotease (mmp) activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.